Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression.
Adam WlodarczykWiesław J CubałaMaria Gałuszko-WęgielnikJoanna SzarmachPublished in: Therapeutic advances in psychopharmacology (2021)
Despite the limitations that this study may be underpowered due to the small sample size, the sample consisted of a heterogeneous TRD population in a single site, and there no blinding of who underwent only acute ketamine administration, our observations indicate ketamine use requires close safety and tolerability monitoring with regards to psychomimetic and dissociative symptoms in TRD-BP and careful management for MDD patients.ClinicalTrials.gov identifier: NCT04226963.
Keyphrases
- major depressive disorder
- pain management
- depressive symptoms
- end stage renal disease
- sleep quality
- ejection fraction
- open label
- newly diagnosed
- healthcare
- bipolar disorder
- liver failure
- prognostic factors
- emergency department
- drug induced
- clinical trial
- intensive care unit
- respiratory failure
- placebo controlled
- hepatitis b virus
- extracorporeal membrane oxygenation